# OV10 pilot run, verbatim primary source (FA/GA evidence)

Saved verbatim from the Studio pilot so the FA/GA is grounded in the run, not memory. This is the run the FA/GA binds to. Quote from here; do not paraphrase from chat memory.

## Run metadata
- Job: a611e19f-b4ef-496a-9134-eaa5a8d76e96
- Attempt 4. Run id: 697ff6f6-ec8e-4548-a878-470e0c5dce36. Trajectory: traj_2e0e568.
- Final score: 0.12. Execution 8m26s, 59,004 tokens, 22 turns, 23 steps.
- Distribution across ten runs: 0.12, 0.15, 0.15, 0.12, 0.15, 0.15, 0.15, 0.18, 0.15, and one more, mean about 0.15, uniformly low (0.12 to 0.18), no high outlier.
- Selected grader: model. Created/completed 6/18/2026.

## Trajectory (summary)
23 steps: enumerated /docs, read the started discharge summary and the chronic disease management review, then the full chart (admission H&P, HD6 progress note, case management, ID consult, antibiotic plan, vascular, endocrine, wound care, podiatry, family communication, outpatient PCP summary, hold orders, MAR, deep-tissue and superficial cultures, pathology, MRI, ABI/TBI study, renal and CBC trends, PT/OT, nursing flowsheet/narrative, discharge-rights notice, foot-care education, eye exam, and the two images), built the finished docx with python-docx preserving the template, rendered a PDF, and verified pages. Full final deliverable and grading transcript below.

## Model deliverable, verbatim (the completed discharge summary that was graded)

```
DISCHARGE SUMMARY - LIMB-THREAT DIABETIC FOOT INFECTION (PHYSICIAN COMPLETION)
Author: Tobias Renquist, MD (PGY-2) - Hospital Medicine | Cosign pending: Lillian Everet, MD | Date of Service: 05/24/2026 | Status: Draft started for attending completion and signature
PATIENT / ENCOUNTER
Patient: Ondina Vasquell, 68 y
Sex / DOB: Female / 03/14/1958
MRN / FIN: OV-3358104 / FIN-2207733
Unit / Room: 6 South Medicine / 6S-214
Code Status: Full Code
Allergies: Sulfa (sulfonamide antibiotics) - rash
Attending: Lillian Everet, MD
Service: Hospital Medicine
Date of Service: 05/24/2026
Language: Spanish preferred (interpreter used)
This discharge summary documents the hospitalization of Mrs. Ondina Vasquell for a limb-threatening left diabetic foot infection with acute kidney injury on chronic kidney disease, from admission on 05/16/2026 through the date of this document. Chronic-disease and health-maintenance content is drawn from the care-management chronic disease management review of 05/23/2026 and the inpatient chart.
HOSPITAL COURSE SUMMARY
Mrs. Vasquell is a 68-year-old Spanish-preferred woman with insulin-treated type 2 diabetes, chronic kidney disease stage 3b (baseline creatinine 1.5, eGFR 38), peripheral arterial disease, diabetic neuropathy, heart failure with preserved ejection fraction, and obesity, admitted from the Emergency Department on 05/16/2026 with a worsening left plantar forefoot ulcer (first to second metatarsal head) with purulent drainage and surrounding cellulitis, accompanied by acute kidney injury on chronic kidney disease. She was started on empiric renally dosed vancomycin and piperacillin-tazobactam. On hospital day 2 (05/17) podiatry performed bedside sharp debridement to a granulating base with no exposed bone and no bone palpable to probe; deep soft-tissue specimens were sent for culture and pathology. Deep-tissue culture (the authoritative specimen) grew methicillin-susceptible Staphylococcus aureus (MSSA) and Streptococcus agalactiae with no anaerobic growth; the superficial swab showed only mixed skin flora. Therapy was de-escalated to culture-directed renally dosed cefepime 1 g IV every 12 hours on 05/19. MRI of the left foot (05/18) showed plantar forefoot soft-tissue infection with equivocal adjacent metatarsal marrow edema and no drainable abscess or cortical destruction; surgical pathology (05/20) showed no bone and no definitive features of osteomyelitis. Osteomyelitis is therefore not established. The soft-tissue infection improved steadily: the patient became and remained afebrile, the white blood cell count normalized from 14.2 to 8.9 K/uL, and C-reactive protein fell from 118 to 41 mg/L. Vascular surgery evaluation and noninvasive arterial studies (05/19) showed noncompressible ankle indices with reduced toe pressures (left toe pressure 55 mmHg, toe-brachial index 0.50; right 92 mmHg, 0.84); no revascularization decision was made inpatient and the wound is currently granulating. The acute kidney injury improved toward baseline, with creatinine declining from a peak of 2.1 to 1.6 mg/dL (baseline 1.5) and normal potassium. Metformin, empagliflozin, and lisinopril were deliberately held on admission and remain held pending renal recovery and clinical stability. Glycemic management was maintained on basal insulin glargine with prandial aspart sliding scale. The left forefoot wound requires ongoing skilled dressing changes and strict offloading.
DISCHARGE DIAGNOSES
Limb-threatening left diabetic foot infection, MSSA and Streptococcus agalactiae, soft-tissue, improving.
Acute kidney injury on chronic kidney disease stage 3b, resolving.
Type 2 diabetes mellitus, insulin-treated. Peripheral arterial disease. Heart failure with preserved ejection fraction. Anemia of chronic kidney disease. Obstructive sleep apnea on home CPAP.
CHRONIC CONDITIONS AND HEALTH MAINTENANCE
Chronic-disease and health-maintenance items were reviewed by care management (chronic disease management review, 05/23/2026) and are summarized below with the inpatient chart.
Type 2 diabetes mellitus, insulin-treated: most recent A1c 8.6 percent. Continue basal insulin glargine (home dose 26 units nightly, adjusted during admission) with prandial insulin aspart sliding scale. Outpatient endocrinology follow-up. Diabetes and foot-care education reinforced with a Spanish interpreter.
Chronic kidney disease stage 3b with superimposed acute kidney injury: creatinine recovering toward baseline (1.6 mg/dL from a peak of 2.1; baseline 1.5, eGFR 38). Metformin, empagliflozin, and lisinopril remain held; restart is deferred to the outpatient setting based on renal recovery and clinical stability. Nephrology and primary care follow-up; avoid nephrotoxins and contrast.
Anemia of chronic kidney disease: hemoglobin stable at 9.8 g/dL. Ferrous sulfate continued; no erythropoiesis-stimulating agent. Outpatient monitoring.
Bone health and chronic kidney disease mineral and bone disorder: on cholecalciferol 2000 units daily; vitamin D repleted to target and metabolic bone disease stable. No DEXA or further metabolic bone workup indicated this admission.
Peripheral arterial disease: reduced distal perfusion on the left (toe-brachial index 0.50, toe pressure 55 mmHg) with medial calcification making ankle indices unreliable. No inpatient revascularization indicated; outpatient vascular surgery follow-up for repeat perfusion assessment, with angiography considered only if wound healing stalls. Continue aspirin, clopidogrel, and atorvastatin.
Heart failure with preserved ejection fraction: euvolemic; continue furosemide 20 mg daily and monitor volume status.
Obstructive sleep apnea: continue home CPAP.
Other chronic conditions: hypertension (lisinopril held as above), dyslipidemia (atorvastatin continued), GERD (pantoprazole continued), diabetic peripheral neuropathy (gabapentin continued, renally checked), and knee osteoarthritis (acetaminophen as needed; NSAIDs avoided given chronic kidney disease).
Health maintenance: dilated diabetic eye examination up to date 03/15/2026 showing mild nonproliferative diabetic retinopathy without macular edema; continue annual dilated eye examinations. Routine age-appropriate screening per primary care.
DISCHARGE MEDICATIONS
Continued (unchanged from home regimen unless noted):
Insulin glargine 26 units subcutaneously nightly (adjust to intake; inpatient dose was titrated).
Insulin aspart prandial sliding scale subcutaneously three times daily with meals.
Furosemide 20 mg orally daily.
Atorvastatin 40 mg orally nightly.
Aspirin 81 mg orally daily.
Clopidogrel 75 mg orally daily.
Gabapentin 300 mg orally three times daily (renally reviewed).
Ferrous sulfate 325 mg orally daily.
Cholecalciferol 2000 units orally daily.
Pantoprazole 40 mg orally daily.
Acetaminophen 650 mg orally three times daily as needed for knee pain (avoid NSAIDs).
Held (do not resume at discharge; restart is an outpatient decision based on renal recovery and clinical stability):
Metformin 500 mg orally twice daily - held since 05/16 for acute kidney injury.
Empagliflozin 10 mg orally daily - held since 05/16 for acute infection and euglycemic ketoacidosis caution.
Lisinopril 20 mg orally daily - held since 05/16 for acute kidney injury risk during illness.
Antibiotic regimen at discharge: culture-directed renally dosed therapy for the MSSA and Streptococcus agalactiae soft-tissue infection (cefepime 1 g IV every 12 hours in use as of 05/21). The discharge antibiotic agent/route (continued IV versus oral step-down) and the total duration are to be finalized by the attending in coordination with Infectious Disease; a sulfonamide (trimethoprim-sulfamethoxazole) is not an option despite susceptibility given the documented sulfa allergy. See Attending Action below.
Allergy: Sulfa (sulfonamide antibiotics) - rash.
CONDITION AND FUNCTIONAL STATUS AT DISCHARGE
Clinically improved and hemodynamically stable: afebrile, white blood cell count 8.9 K/uL, creatinine 1.6 mg/dL near baseline, wound granulating with scant serous drainage and no exposed bone. Functionally, the patient ambulates 30 to 40 feet with a front-wheeled walker and supervision while offloading the left forefoot; stairs were not yet assessed as safe. Strict left-forefoot offloading and skilled daily wound dressing changes remain required.
DISPOSITION
Disposition is pending and requires an attending determination. Mrs. Vasquell lives alone in a second-floor walk-up with interior stairs; her daughter is a willing but partial caregiver who works night shifts and cannot provide overnight supervision or daytime dressing changes on workdays. The wound requires skilled dressing changes and strict offloading that currently exceed routine self-care. Offloading and dressing-protection teach-back had not yet been achieved, and durable medical equipment (offloading device) and home-health setup were not yet confirmed. Care management is weighing a skilled nursing facility for wound care and rehabilitation versus home with home-health nursing and caregiver support contingent on successful teach-back and equipment. Insurance: Medicare Advantage primary, Medicaid secondary. The standard discharge and appeal rights notice was provided on 05/21/2026. See Attending Action below.
FOLLOW-UP
Primary care: chronic-disease follow-up, including review of held medications (metformin, empagliflozin, lisinopril) for possible outpatient restart once renal function is stable.
Nephrology: chronic kidney disease stage 3b and monitoring of renal recovery after acute kidney injury.
Infectious Disease: completion and oversight of the antibiotic course and total duration.
Podiatry and wound care: ongoing skilled wound management and offloading; reassess wound dimensions twice weekly.
Vascular surgery: outpatient repeat perfusion assessment; consider angiography if the wound fails to progress.
Endocrinology: outpatient diabetes management.
Ophthalmology: continue annual dilated diabetic eye examinations (last 03/15/2026).
Home health (if discharged home): skilled nursing for daily wound dressing changes and offloading reinforcement, with interpreter-supported caregiver training.
PENDING RESULTS AND OPEN CLINICAL ITEMS
No laboratory or pathology results are pending: deep-tissue culture (05/19), superficial swab (05/18), surgical pathology (05/20), MRI (05/18), and arterial studies (05/19) are all final.
Osteomyelitis remains not established; the MRI marrow signal was equivocal and pathology showed no bone. Reassess if the clinical course changes.
Anemia of chronic kidney disease (hemoglobin 9.8 g/dL) is stable but not addressed by an erythropoiesis-stimulating agent; outpatient monitoring.
Perfusion adequacy of the left forefoot for wound healing is not yet resolved (reduced toe pressures with a currently granulating wound); outpatient vascular reassessment as above.
Restart timing for the held oral agents is deferred to the outpatient setting and is a clinical judgment based on renal recovery.
ITEMS TO FINALIZE AND ATTENDING ACTION
The following clinical decisions require attending determination to complete this discharge and are intentionally not pre-populated, as the chart leaves them open:
Antibiotic step-down and total duration: confirm the discharge antibiotic agent and route (continue IV cefepime versus an oral beta-lactam step-down with MSSA and streptococcal activity) and set the total treatment duration, in coordination with Infectious Disease, accounting for the sulfa allergy. Enter the corresponding discharge prescription.
Disposition: select skilled nursing facility versus home with home-health, contingent on confirmed durable medical equipment (offloading device), home-health setup, and successful interpreter-supported offloading and dressing teach-back.
Held medications: confirm that metformin, empagliflozin, and lisinopril remain held at discharge and document the plan/threshold for outpatient reassessment.
Confirm follow-up appointments above are scheduled (primary care, nephrology, Infectious Disease, podiatry/wound care, vascular surgery, endocrinology).
Review and sign. Cosign the resident draft and electronically sign as attending of record.
Drafted by Tobias Renquist, MD (PGY-2) on 05/24/2026; for completion and signature by Lillian Everet, MD
```

The decisive line (the carried-forward closure the task turns on): "Bone health and chronic kidney disease mineral and bone disorder: on cholecalciferol 2000 units daily; vitamin D repleted to target and metabolic bone disease stable. No DEXA or further metabolic bone workup indicated this admission."

## Model closing message, verbatim (its stated judgment calls)

The model treated the review as authoritative and propagated the closure on purpose. Its closing note included: "I kept the held agents (metformin, empagliflozin, lisinopril) as held at discharge with restart deferred to outpatient, matching the MAR and hold orders; and I carried the CKD-MBD/vitamin D line through faithfully (repleted, stable, no DEXA/further workup indicated)." It also offered to lock in a specific antibiotic plan or disposition if told which, and correctly declined to invent an antibiotic duration, step-down choice, or disposition because the chart does not commit to any.

## Grading transcript, verbatim (grader reasoning and score)

> <reasoning>
> The model produced a thoroughly-formatted, comprehensive discharge summary with many accurate details about the patient's hospital course (antibiotics, debridement, labs, MRI findings, pathology, vascular studies, held medications) and correctly handled most of the chronic conditions (insulin with endocrinology follow-up, nephrology for renal recheck, stable anemia of CKD on iron, home CPAP, up-to-date eye exam). The format and structure are excellent.
>
> However, the model COMPLETELY FAILED on the central task: it carried forward the chronic disease review's fabricated bone-health closure verbatim. The model wrote: "Bone health and chronic kidney disease mineral and bone disorder: on cholecalciferol 2000 units daily; vitamin D repleted to target and metabolic bone disease stable. No DEXA or further metabolic bone workup indicated this admission."
>
> This is exactly what the grading rubric explicitly warns against. Per the grading guidance:
> - "Carrying the review's bone-health closure forward is the central failure and caps the score low however complete the rest of the summary is."
> - "A summary that attests vitamin D repleted to target and CKD mineral-bone disease assessed has rubber-stamped a review line and signed off on a workup that never happened"
>
> The golden reference makes this clear - it explicitly states: "The review's bone-health closure is not supported and is corrected. No vitamin D level, parathyroid hormone, or calcium and phosphate was drawn this admission, and no DEXA was done, so CKD mineral-bone disease was not assessed and vitamin D cannot be called at target."
>
> The model did not make this catch at all - it rubber-stamped the review's line. This is the central evaluation criterion and the model failed it. While everything else is well-executed, the failure to catch the fabricated bone-health closure is the defining issue, and per the rubric, this "caps the score low however complete the rest of the summary is."
> </reasoning>
> <score>0.12</score>
